Prithvi Mruthyunjaya, MD
Retina Specialist · Stanford, CANPI 1073670477
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $64,195 of the $74,237 with a category attached, or 86.5%. Alcon accounts for 73.4% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2023 at $23,334 and has fallen 97.5% since, to $584 in 2025.
Across 64 payments — averaging $1159.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$55K
- Dutch Ophthalmic, USA$5K
- Amgen$5K
- Genentech USA, Inc.$5K
- Bausch & Lomb Americas Inc.$1K
- Immunogen, Inc.$1K
- plus $2K from 11 others
Across 37 payments — averaging $10,002 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Apellis Pharmaceuticals, Inc.$240K
- Genentech, Inc.$130K
What the payments were for
- Consulting fees$64,19586%
- Speaking & faculty fees$1,0351%
- Travel & lodging$5,3617%
- Food & beverage$3,6465%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 30 | $54,512 |
| Dutch Ophthalmic, USA | 5 | $5,478 |
| Amgen | 2 | $4,915 |
| Genentech USA, Inc. | 5 | $4,884 |
| Bausch & Lomb Americas Inc. | 2 | $1,147 |
| Immunogen, Inc. | 2 | $1,127 |
| Alcon Research LLC | 1 | $700 |
| Alimera Sciences, Inc. | 3 | $357 |
| Genentech, Inc. | 3 | $315 |
| Regeneron | 2 | $180 |
| Astellas Pharma US Inc | 1 | $149 |
| Immunocore Limited | 2 | $125 |
| Carl Zeiss Meditec USA, Inc. | 1 | $123 |
| Eyepoint US, Inc. | 1 | $111 |
| Apellis Pharmaceuticals, Inc. | 2 | $58 |
| Carl Zeiss Meditec, Inc. | 1 | $29 |
| Novartis | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Constellation$39,548
- NGENUITY$9,245
- Luxor$9,100
- Alcon Greishaber Finesse$9,100
- EVA, combined machine$5,399
- Lucentis$4,812
- TISSUEBLUE$2,250
- XIPERE$1,035
- STELLARIS ELITE$1,035
- Iluvien$357
- Unity$310
- ARTEVO 800$123
- VABYSMO$120
- STELLARIS$112
- EYP-1901$111
How this compares
$74,237 in reported general payments places this provider in the 85th percentile of 187 retina specialist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 47 | $1,929 |
| Ketorolac Tromethamine | 33 | $361 |
| Brimonidine Tartrate | 12 | $329 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Stanford
- Ehsan RahimyStanford$1.5M
- Diana DoStanford$318K
- Theodore LengStanford$223K
- Charles DeboerStanford$79K
- Mary HartnettStanford$73K
- Dilsher DhootSanta Barbara$1.9M
- Darius MoshfeghiPalo Alto$1.4M
- Nathan SteinleSanta Barbara$1.1M
- Roger GoldbergWalnut Creek$1.1M
- Baruch KuppermannIrvine$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.